Page 136 - 80 guidelines for the treatment of malaria_opt
P. 136

nd
              Guidelines for the treatment of malaria – 2  edition


            ANNEX 6
            resistance to antimalarial medicines







            a6.1  introduction

            Currently, there are no bedside tests for determining the susceptibility of the malaria
            parasite to antimalarials. Monitoring is, therefore, needed to determine geographical
            trends in susceptibility and the emergence and spread of drug resistance. The information
            obtained will help guide treatment choices and predictions about future resistance
            patterns.

            The greatest problem with drug resistance occurs with Plasmodium falciparum. Resistance
            of P. falciparum is of particular concern because of the enormous burden of disease caused
            by this species, its lethal potential, the propensity for epidemics, and the cost of candidate
            replacement drugs for areas with established drug resistance. Chloroquine resistance
            does occur in P. vivax, especially in western Oceania, but there are very few reports of
            resistance in P. malariae or P. ovale (although there have also been very few studies).

            This annex defines resistance, examines how it arises and spreads, and describes ways
            in which it can be monitored.








            a6.2  definition

            Antimalarial drug resistance is defined as the ability of a parasite strain to survive and/
            or multiply despite the proper administration and absorption of an antimalarial drug in
            the dose normally recommended. Drug resistance to an antimalarial compound results
            in a right shift in the concentration-effect (dose-response) relationship (Fig. A6.1). As
            the pharmacokinetic properties of antimalarials vary widely in different individuals, the
            definition of resistance should probably also include a “normal” plasma concentration
            profile for the active drug concerned or, in the case of a prodrug (a drug that is not active in
            the ingested form and requires chemical conversion through metabolic processes to become
            pharmacologically active), a “normal” profile of the biologically active metabolite.
            Antimalarial drug resistance is not necessarily the same as malaria “treatment failure”,
            which is a failure to clear malarial parasitaemia and/or resolve clinical symptoms despite
            the administration of an antimalarial. So while drug resistance may lead to treatment

   122
   131   132   133   134   135   136   137   138   139   140   141